Active • Host: • AA: 1-740 • Tag: C-terminal His • MW: 86.7 kDa
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

ACE2 (human, recombinant)

Item No. 30587

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Synonyms
  • ACEH
  • ACE-related Carboxypeptidase
  • Angiotensin-converting Enzyme Homolog
  • Angiotensin-converting Enzyme 2
  • Metalloprotease MPROT15
Purity
≥90% estimated by SDS-PAGE
Source
Active recombinant human C-terminal His-tagged ACE2 expressed in HEK293 cells
Amino Acids
1-740
MW
86.7 kDa
Formulation (Request formulation change)
50 mM PIPES, pH 7.0, with 300 mM sodium chloride, 5% mannitol, 5% trehalose, 0.01% Tween 20, and 25% glycerol
UniProt Accession №
Q9BYF1
Shipping & Storage Information
Storage
-80°C
Shipping
Dry ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    20 µg

    $401

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Angiotensin-converting enzyme 2 (ACE2) is a carboxypeptidase and homolog of ACE1 that is encoded by ACE2 in humans.1,2 It is a type I transmembrane protein composed of a cytoplasmic tail and an extracellular domain containing an HEMGH motif, characteristic of zinc-metallopeptidases, which exhibits carboxymonopeptidase activity.1 ACE2 is expressed in vascular endothelial cells where it catalyzes the conversion of angiotensin II to the vasodilatory peptide angiotensin 1-7 to regulate systemic blood pressure and angiotensin I to angiotensin 1-9, a peptide that counter-regulates the function of angiotensin II.1,2,3 It is also expressed in the epithelial cells of the kidney, heart, lung, small intestine, and liver and has roles in fluid homeostasis, cardiac contractility, and amino acid absorption, as well as the prevention of pulmonary fibrosis and hypertension. ACE2 also acts as a functional receptor for severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 to facilitate viral entry into host cells.4,5 Cayman's ACE2 (human, recombinant) protein can be used for ELISA, enzyme assay, surface plasmon resonance (SPR), and Western blot (WB) applications.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Perlot, T., and Penninger, J.M. ACE2 – From the renin-angiotensin system to gut microbiota and malnutrition. Microbes Infect. 15(13), 866-873 (2013).

    2. Santos, R.A.S., Sampaio, W.O., Alzamora, A.C., et al. The ACE2/angiotensin-(1-7)/MAS axis of the renin-angiotensin system: Focus on angiotensin-(1-7). Physiol. Rev. 98(1), 505-553 (2018).

    3. Ocaranza, M.P., Moya, J., Barrientos, V., et al. Angiotensin-(1—9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis. J. Hypertens. 32(4), 771-783 (2014).

    4. Hoffmann, M., Kleine-Weber, H., Schroeder, S., et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2), 271-280 (2020).

    5. Gurwitz, D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev. Res. 81(5), 537-540 (2020).